90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors, Inflammatory Bowel Diseases
Conclusions The 90-day CDI-specific readmission rate after the index admission of IBD flares was 0.1%. We found risk factors for CDI-associated readmissions such as history of Parkinson's disease, prior CDI, HIV-positive status, and alcohol abuse disorder. Finally, our study also revealed a high health care cost, charges, and burden. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function
In this study, however, we delineated their specific gene and protein expression profiles and identified several distinct goblet cell populations that form two differentiation trajectories. One distinct subtype, the intercrypt goblet cells (icGCs), located at the colonic luminal surface, produced mucus with properties that differed from the mucus secreted by crypt-residing goblet cells. Mice with defective icGCs had increased sensitivity to chemically induced colitis and manifested spontaneous colitis with age. Furthermore, alterations in mucus and reduced numbers of icGCs were observed in patients with both active and rem...
Source: ScienceNOW - April 15, 2021 Category: Science Authors: Nyström, E. E. L., Martinez-Abad, B., Arike, L., Birchenough, G. M. H., Nonnecke, E. B., Castillo, P. A., Svensson, F., Bevins, C. L., Hansson, G. C., Johansson, M. E. V. Tags: Cell Biology, Molecular Biology, Online Only r-articles Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

What Are Indications for a Ileostomy?
Discussion There are three types of inflammatory bowel disease (IBD): Crohn’s disease (CD) – can affect entire gastrointestinal tract but often is discontinuous (i.e., has skipped areas), has transmural inflammation and disease, has granulomas Ulcerative colitis (UC) – affects the colon, is continuous (i.e., has no skipped areas) and has superficial mucosal ulcerations Unclassified IBD – has chronic colitis but not specific features of CD or UC The specific pathogenesis appears to be multifactorial with having a genetic predisposition (1.6 – 30% risk of developing UC if patient has first deg...
Source: PediatricEducation.org - March 29, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Inflammatory Burden Predicts Cancer Risk in Ulcerative Colitis Inflammatory Burden Predicts Cancer Risk in Ulcerative Colitis
The cumulative burden of histologic inflammation is a strong predictor of colorectal neoplasia risk in ulcerative colitis, according to a recent case-control study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

A T-cell stimulatory protein and interleukin-10 synergize to prevent gut inflammation
(University of Alabama at Birmingham) Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice. The study will aid the understanding of, and future research into, this immune disorder, which includes Crohn's disease and ulcerative colitis. About 1.6 million Americans have inflammatory bowel disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Common inflammatory bowel disease treatment linked to reduced COVID-19 antibody response
(University of Exeter) The findings arose from the CLARITY study, which recruited 6,935 patients with Crohn's disease and ulcerative colitis from 92 UK hospitals between September and December 2020. It found that fewer than half of people with IBD who were treated with infliximab had detectable antibodies after SARS-CoV-2 infection, the coronavirus that causes COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news

New dawn in the war on a debilitating bowel disease
Father-of-two Garry Naftarski was one of the first British patients to try a new ulcerative colitis drug called filgotinib - and it transformed his life. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2021 Category: Consumer Health News Source Type: news

Mayo Clinic Q & amp;A podcast: The increasing prevalence of inflammatory bowel disease
Inflammatory bowel disease is common, and it is becoming more common in many populations. Dr. William Faubion Jr., a Mayo Clinic gastroenterologist, says inflammatory bowel disease is an umbrella term that covers Crohn's disease and ulcerative colitis, and that inflammatory bowel disease is an emerging public health problem. "The most recent estimates would be that, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 16, 2021 Category: Databases & Libraries Source Type: news

Adalimumab Earns FDA Approval for Ulcerative Colitis in Children Adalimumab Earns FDA Approval for Ulcerative Colitis in Children
Adalimumab has received approval from the Food and Drug Administration for use in pediatric patients aged 5 years and older with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2021 Category: Gastroenterology Tags: Pediatrics News Alert Source Type: news

Immune-mediated Diseases and Risk of IBD Immune-mediated Diseases and Risk of IBD
Are individuals with other immune-mediated diseases at greater risk of developing ulcerative colitis or Crohn's disease?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Humira (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 24, 2021 Category: Drugs & Pharmacology Source Type: news

Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
Listen to FDA Drug Safety Podcast on Drug Safety Communication titled "Initial safety trial results find increased risk of serious heart-related problems and cancer with tofacitinib (Xeljanz, Xeljanz XR) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 8, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication -  Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine
The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to tumor necrosis factor (TNF) inhibitors. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 4, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
Preliminary safety trial results show an increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib). FDA will evaluate the results. Patients should not stop taking the medicine without first talking to their health care professionals. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 4, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

My Life With Ulcerative Colitis
An amateur athlete makes peace with his ulcerative colitis diagnosis and refuses to let his condition undermine his goals. (Source: WebMD Health)
Source: WebMD Health - February 3, 2021 Category: Consumer Health News Source Type: news

Surgery to heal inflamed gut may create new target for disease
(NYU Langone Health / NYU School of Medicine) A surgical procedure meant to counter ulcerative colitis, an immune disease affecting the colon, may trigger a second immune system attack, a new study shows. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 2, 2021 Category: Biology Source Type: news

Burden of ulcerative colitis substantial in Japan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Why You Need an Ulcerative Colitis Support Community
When you have ulcerative colitis (UC), it can help to find people who understand what you’re going through. Learn why you should find your UC support community and how to make it happen. (Source: WebMD Health)
Source: WebMD Health - January 28, 2021 Category: Consumer Health News Source Type: news

Ghosted After a UC Diagnosis: How to Respond
Did a friend or potential romantic partner stop taking to you after your ulcerative colitis diagnosis? Learn why it happens and what you can do about it. (Source: WebMD Health)
Source: WebMD Health - January 28, 2021 Category: Consumer Health News Source Type: news

What a Doctor Wants You to Know About Ulcerative Colitis
From treatment to remission, symptoms to support, here’s what a doctor who treats it every day wants you to know about ulcerative colitis. (Source: WebMD Health)
Source: WebMD Health - January 27, 2021 Category: Consumer Health News Source Type: news

How Can Emotional Support Animals Help With Ulcerative Colitis
Learn how emotional support animals can help with the stress that often comes with ulcerative colitis flare-ups. (Source: WebMD Health)
Source: WebMD Health - January 26, 2021 Category: Consumer Health News Source Type: news

How to Advocate for Yourself With UC
When you have ulcerative colitis (UC), you have to be able to stand up for yourself when it comes to getting the proper medical care and making sure you’re taking care of yourself. Learn how -- from doctors who treat UC every day. (Source: WebMD Health)
Source: WebMD Health - January 22, 2021 Category: Consumer Health News Source Type: news

5-ASA-intolerance and Increased Risk of Colectomy for UC 5-ASA-intolerance and Increased Risk of Colectomy for UC
5-aminosalicylate is first-line therapy in ulcerative colitis, but some patients cannot tolerate its side effects. Are these patients at higher risk of colectomy?Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

5-ASA-intolerance and Increased Risk of Colectomy for UC 5-ASA-intolerance and Increased Risk of Colectomy for UC
5-aminosalicylate is first-line therapy in ulcerative colitis, but some patients cannot tolerate its side effects. Are these patients at higher risk of colectomy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Ultrasound predicts ulcerative colitis treatment response
Ultrasound scans may help physicians predict which patients with severe ulcerative...Read more on AuntMinnie.comRelated Reading: Ultrasound predicts which kids benefit from colitis meds Cinematic rendering complements CT in diagnosing colitis Immuno-PET could aid patients with inflammatory diseases 3 ways cinematic rendering can bolster colon evaluation PET/CT enhances detection of inflammatory bowel disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 11, 2021 Category: Radiology Source Type: news

Researchers engineer novel disease model to identify potential targets for ulcerative colitis drugs
(Cleveland Clinic) As reported in Nature Communications, researchers from Cleveland Clinic's Lerner Research Institute have developed a novel, patient-derived model of ulcerative colitis, which will help advance studies into new treatments for the chronic inflammatory bowel disease. The team used the model to identify a promising target that could be inhibited to slow disease progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

UC: Can the Autoimmune Protocol Diet Help?
Can a diet called the autoimmune protocol, or AIP, improve your ulcerative colitis? Possibly. Some people say elimination diets, like AIP and others, put their disease in remission. (Source: WebMD Health)
Source: WebMD Health - December 21, 2020 Category: Consumer Health News Source Type: news

Can Marijuana or CBD Help With Ulcerative Colitis?
Can marijuana or CBD help manage the symptoms of ulcerative colitis? (Source: WebMD Health)
Source: WebMD Health - December 18, 2020 Category: Consumer Health News Source Type: news

UC: How Can It Affect Your Sex Life?
If you have ulcerative colitis, you might be wondering whether it’s possible to have a satisfying sex life. The short answer is yes. (Source: WebMD Health)
Source: WebMD Health - December 16, 2020 Category: Consumer Health News Source Type: news

Does Histologic Remission Offer Benefit for UC Patients? Does Histologic Remission Offer Benefit for UC Patients?
Do ulcerative colitis patients in endoscopic remission obtain additional benefit from achieving histologic remission?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy
This long-term extension study assessed the efficacy and safety of one additional year of ustekinumab maintenance treatment in patients originally manifesting moderate-to-severe ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Consumer Health: Treating Crohn's disease and ulcerative colitis
Inflammatory bowel disease, or IBD, is an umbrella term used to describe disorders that involve chronic inflammation of your digestive tract. IBD can be debilitating and sometimes leads to life-threatening complications. Crohn's disease and ulcerative colitis are two types of IBD. Crohn's disease is characterized by inflammation of the lining of your digestive tract, which often [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 9, 2020 Category: Databases & Libraries Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Vitamin D regulates calcium in intestine differently than previously thought
(Rutgers University) A Rutgers study has discovered that vitamin D regulates calcium in a section of the intestine that previously was thought not to have played a key role. The findings have important implications on how bowel disease, including ulcerative colitis and Crohn's disease, may disrupt calcium regulation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

Key Studies in Ulcerative Colitis From ACG 2020 Virtual Key Studies in Ulcerative Colitis From ACG 2020 Virtual
Highlights in ulcerative colitis from the ACG 2020 virtual meeting include the OCTAVE tofacitinib trial program, the long-term and comparative efficacy of vedolizumab, and long-term colectomy trends.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Kurogane holly contains anti-cancer compounds for IBS patients
(Natural News) Colitis-associated cancer (CAC) is one of the most serious complications of inflammatory bowel disease (IBD), an umbrella term for disorders that cause chronic inflammation of the digestive tract. An important risk factor for colon cancer, IBDs – either ulcerative colitis or Crohn s disease – often precede CAC, which is a type of inflammation-driven... (Source: NaturalNews.com)
Source: NaturalNews.com - November 17, 2020 Category: Consumer Health News Source Type: news

Tool Predicted Vedolizumab Nonresponse in Routine Practice Tool Predicted Vedolizumab Nonresponse in Routine Practice
Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 13, 2020 Category: Internal Medicine Tags: Gastroenterology News Source Type: news

Optimum Number of Biopsies to Assess Inflammation in UC Optimum Number of Biopsies to Assess Inflammation in UC
What are the minimum number of biopsies required to adequately assess histological disease activity in ulcerative colitis patients?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Athos Therapeutics Announces Appointment of Chief Business Officer
LOS ANGELES, Nov. 2, 2020 -- (Healthcare Sales & Marketing Network) -- Athos Therapeutics Inc., a late pre-clinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and c... Biopharmaceuticals, Personnel Athos Therapeutics, Ulcerative Colitis, Crohn's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2020 Category: Pharmaceuticals Source Type: news

Tofacitinib Retreatment Effective for Ulcerative Colitis Tofacitinib Retreatment Effective for Ulcerative Colitis
Clinical response can be recaptured in patients who have had to interrupt treatment with tofacitinib, a JAK inhibitor, for up to 2 months, an analysis of data from the OCTAVE extension trial shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Long-term Safety of Vedolizumab for Inflammatory Bowel Disease Long-term Safety of Vedolizumab for Inflammatory Bowel Disease
This paper details the final results from the GEMINI study, which evaluated the long-term safety of vedolizumab in patients with ulcerative colitis or Crohn's disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Can Ulcerative Colitis Be Cured With Surgery?
Title: Can Ulcerative Colitis Be Cured With Surgery?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - October 21, 2020 Category: Nutrition Source Type: news

DDT COA #000040: Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS)
Clinical Outcome Assessments (COA) Qualification Submissions Office of Drug Evaluation (ODE) III Division of Gastroenterology and Inborn Error Products (DGIEP) DDT COA Number DDT COA #000040 (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 6, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Ulcerative Colitis: Adopting the AGA's Guidelines Ulcerative Colitis: Adopting the AGA's Guidelines
Three expert gastroenterologists discuss how this latest update reshapes the management of moderate to severe ulcerative colitis.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2020 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Predictors of Histological Remission in Ulcerative Colitis Predictors of Histological Remission in Ulcerative Colitis
This study aimed to identify the feasibility and predictors of achieving histologic remission in patients with ulcerative colitis treated-to-target of endoscopic healing.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Drug found to correct gene defect that causes immune-driven gut leakiness
(University of California - Riverside) A team of researchers led by biomedical scientist Declan McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine. " Our work could help improve identification of patients who will be better responders to this drug, " says McCole, a professor of biomedical sciences in the School of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2020 Category: International Medicine & Public Health Source Type: news